

In silico Assessment of the Genotypic Distribution of Virulence and Antibiotic Resistance Genes in *Pseudomonas aeruginosa*

Nusrat Nahar^{*}, Sharmeen Asad, Tufael Ahmed, Nurul Islam Setu, Md. Shahidulla Kayser, Md. Shariful Islam, Md. Kamrul Islam, Muhammed Mahfuzur Rahman, D. A. Anwar Al Aman, Ridwan Bin Rashid

Computational Chemistry and Bioinformatics Laboratory, Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh.

ARTICLE INFO

Article history:

Received on: 02/04/2017

Accepted on: 30/05/2017

Available online: 30/07/2017

Key words:

Antibiotic resistance genes, Genotype, PCR, *Pseudomonas aeruginosa*, Pulsed-field gel electrophoresis, Virulence genes.

ABSTRACT

Pseudomonas aeruginosa harbours virulence and antibiotic resistance genes that contribute to life-threatening infections. *In silico* PCR amplification detected both virulence and antibiotic resistance genes of eighteen *Pseudomonas aeruginosa* isolates. L lipoprotein (*oprL*) gene was found in 72.22% of the isolates and is used usually to rapidly identify *Pseudomonas aeruginosa* species. Alkaline protease (*apr*) was detected in 66.67% of the isolates. Protein biosynthesis inhibited by exotoxin A (*exoA*), was found in 55.56% of the isolates. Fifty percent (n=9) of the isolates had the exoenzyme S (*exoS*) and elastase (*lasB*) genes. Thirteen isolates (72.22%) which harboured the phospholipid C (*plcH*) genes, were also found to be positive for rhamnolipid AB (*rhlAB*) genes. Thirteen isolates (72.22%) were found to possess alginate (*algD*) and neuraminidase (*nan2*) genes, respectively. *Pseudomonas aeruginosa* PA7 harboured both *aph(3'')* and *aph(6)-1d* genes. Only sulfonamide resistance gene, *sulI* was present in 11.11% (n=2) of the isolates. Beta-lactamase gene, *bla_{TEM}* was present in only one isolate and no tetracycline resistance gene was found. Fluoroquinolone resistance-determining region of the *gyrA* and *parC* genes were present in fourteen (77.78%) and thirteen (72.22%) isolates, respectively. *Pseudomonas aeruginosa* NCGM2.S1 is a multidrug resistant bacterium since it harboured class 1 integrase gene. *In silico* pulsed-field gel electrophoresis (PFGE) analysis was able to group eighteen isolates into three genotypes. Gene distribution pattern within genotypes was almost similar and not dependent on genotypes. The data generated here helps to predict virulence and antibiotic resistance profile of *Pseudomonas aeruginosa* species based on genotype.

INTRODUCTION

Pseudomonas aeruginosa is a gram-negative opportunistic pathogen that infects virtually all tissues. Fegan *et al.* (1990) reported that *P. aeruginosa* is colonized on respiratory tract and contributed to cystic fibrosis infection. Yetkin *et al.* (2006) reported that *P. aeruginosa* is responsible for nosocomial infection and affects patients in intensive care units. Pollack (2000) stated that immunocompromised cancer patients, burn

patients and catheterized patients also suffer from serious infections that are caused by *P. aeruginosa*. Trautner and Darouiche (2004) reported that biofilms developed by *P. aeruginosa* are attached to the site of infection and caused chronic and recurrent infections. *Pseudomonas* is responsible for waterborne outbreaks of dermatitis, conjunctivitis and otitis media (Adesoji *et al.*, 2015). Van Delden and Iglewski (1998) stated that virulence properties of *P. aeruginosa* are tightly regulated by cell to cell signaling systems. Virulence factors of *P. aeruginosa* are divided into specific groups such as adhesins or other secreted exotoxins. Bradbury *et al.* (2010) reported that type I (TISS), type II (T2SS) or type III (T3SS) secretion system actively secreted exotoxins. Bradbury *et al.* (2010) also stated that previous studies have found the association of virulence factors with different diseases.

Corresponding Author

Nusrat Nahar, Computational Chemistry and Bioinformatics Laboratory, Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh. Email: nusratnahar17@gmail.com.

Protein synthesis inhibiting exotoxin A was reported earlier by Thamir and Al-Jubori (2014). Khattab *et al.* (2015) demonstrated that PCR based amplification of L lipoprotein (*oprL*) is used for identification of the species of *Pseudomonas*. Pollack (2000) demonstrated that multidrug-resistant *P. aeruginosa* is medically important and caused several infections. Antibiotic resistance genes can be transferred between different microorganisms with the help of integrase gene, *intI* (Adesoji *et al.*, 2015). Yah *et al.* (2006), Bonomo and Szabo (2006), Chen *et al.* (2009) reported that plasmids or transposons also contributed to developing multidrug-resistant *Pseudomonas*.

Strateva and Yordanov (2009) concluded that risk factors identification for multidrug-resistant *Pseudomonas* is important to minimize this problem. Several clinical studies are needed to minimize severe infections caused by *Pseudomonas* and maximize the outcomes in the treatment of infectious diseases. The aim of the present study is to characterize the virulence and antibiotic resistance property of 18 *Pseudomonas aeruginosa* isolates by PCR and to find the distribution in genotypes based on pulsed field gel electrophoresis (PFGE).

MATERIALS AND METHODS

Strains used in the study

Strains used in the study are summarized in Table 1.

Primer used in the study

Primer used for virulence and antibiotic resistance gene detection in the study are summarized in Table 2 and 3.

PCR amplification

In silico PCR amplification was done in the website <http://insilico.ehu.es/PCR/> (San Millán *et al.*, 2013; Bikandi *et al.*, 2004).

PFGE digestion

Pulsed field gel electrophoresis (PFGE) digestion was done in the website <http://insilico.ehu.es/digest/> (San Millán *et al.*, 2013; Bikandi *et al.*, 2004). The enzyme used for the digestion was *PacI*. Banding patterns were scored in a binary matrix and a dendrogram was constructed using Complete Linkage method by SPSS 16 (IBM, USA).

Table 1: Name of the isolates.

Number	Isolate
1	NC_002516 <i>Pseudomonas aeruginosa</i> PAO1
2	NC_020912 <i>Pseudomonas aeruginosa</i> B136-33
3	NC_018080 <i>Pseudomonas aeruginosa</i> DK2
4	NC_023066 <i>Pseudomonas aeruginosa</i> LES431
5	NC_011770 <i>Pseudomonas aeruginosa</i> LESB58
6	NC_017548 <i>Pseudomonas aeruginosa</i> M18
7	NC_023019 <i>Pseudomonas aeruginosa</i> MTB-1
8	NC_017549 <i>Pseudomonas aeruginosa</i> NCGM2.S1
9	NC_022808 <i>Pseudomonas aeruginosa</i> PA1
10	NC_022806 <i>Pseudomonas aeruginosa</i> PA1R
11	NC_009656 <i>Pseudomonas aeruginosa</i> PA7
12	NC_022594 <i>Pseudomonas aeruginosa</i> PAO1-VE13 genome
13	NC_022591 <i>Pseudomonas aeruginosa</i> PAO1-VE2 genome
14	NC_022361 <i>Pseudomonas aeruginosa</i> PAO581 genome
15	NC_021577 <i>Pseudomonas aeruginosa</i> RP73
16	NC_023149 <i>Pseudomonas aeruginosa</i> SCV20265
17	NC_008463 <i>Pseudomonas aeruginosa</i> UCBPP-PA14
18	NC_022360 <i>Pseudomonas aeruginosa</i> c7447m genome

Table 2: Primer for virulence gene detection.


Target	Gene	Primer	Amplicon Size bp	Reference
L lipoprotein	<i>oprL</i>	ATG GAAATGCTGAAATTCGGC CTTCTTCAGCTCGACGCGACG	504	De Vos <i>et al.</i> , 1997
Alkaline protease	<i>apr</i>	TGTCCAGCAATTCTTTGC CGTTTTCCACGGTGACC	1017	Fazeli and Momtaz, 2014
Exotoxin A	<i>toxA</i>	GGAGCGCAACTATCCCACT TGGTAGCCGACGAACACATA	250	Sabharwal <i>et al.</i> , 2014
Exoenzyme S	<i>exoS</i>	CTTGAAGGGACTCGACAAGG TTCAGGTCCGCGTAGTGAAT	504	Stover <i>et al.</i> , 2000
Elastase	<i>lasB</i>	GGAATGAACGAAGCGTTTCCGAC TGGCGTCGACGAACACTCG	283	Fazeli and Momtaz, 2014
Rhamnolipid AB	<i>rhlAB</i>	TCATGGAATTGTACAACCGC ATACGGCAAAATCATGGCAAC	151	Sabharwal <i>et al.</i> , 2014
Phospholipase C	<i>plcH</i>	GAAGCCATGGGCTACTTCAA AGAGTGACGAGGAGCGGTAG	307	Sabharwal <i>et al.</i> , 2014
Alginate	<i>algD</i>	ATGCGAATCAGCATCTTTGGT CTACCAGCAGATGCCCTCGGC	1311	Stover <i>et al.</i> , 2000
Putative neuraminidase	<i>nan2</i>	ACAACAACGGGGACGGTAT GTTTTGCTGATGCTGGTTCA	1161	Stover <i>et al.</i> , 2000

Table 3: Primer for antibiotic resistance gene detection.

Target	Gene	Primer sequence (5'-3')	Amplicon size bp	Reference
Class 1 integrase gene	<i>int1</i>	CCTCCCGCACGATGATC TCCACGCATCGTCAGGC	270	Houang <i>et al.</i> , 2003
Class 2 integrase gene	<i>int2</i>	TTATTGCTGGGATTAGGC ACGGCTACCCTCTGTTATC	233	Roe <i>et al.</i> , 2003
Variable region of class 1 integron	<i>vt1</i>	GGCATCCAAGCAGCAAG AAGCAGACTTGACCTGA	Variable	Hall and Collis, 1995
Variable region of class 1 integron	<i>vt2</i>	CGGGATCCCGGACGGCATGCACGATTGTA GATGCCATCGCAAGTACGAG	Variable	White <i>et al.</i> , 2001
Sulfonamide resistance gene	<i>sul1</i>	CGGCGTGGGCTACCTGAACG GCCGATCGCGTGAAGTTCCG	433	Vinue <i>et al.</i> , 2010
Sulfonamide resistance gene	<i>sul2</i>	GCGCTCAAGGCAGATGGCATT GCGTTTGATACCGGCACCCGT	293	Vinue <i>et al.</i> , 2010
Sulfonamide resistance gene	<i>sul3</i>	TCAAAGCAAAATGATATGAGC TTCAAGGCATCTGATAAAGAC	787	Vinue <i>et al.</i> , 2010
Streptomycin resistance gene	<i>aph (3'')</i>	GCTCAAAGGTCGAGGTGTGG CCAGTTCTCTTCGGCGTTAG	515	van Overbeek <i>et al.</i> , 2001
Streptomycin resistance gene	<i>aph (6)-1d</i>	GACTCCTGCAATCGTCAAGG GCAATGCGTCTAGGATCGAG	560	van Overbeek <i>et al.</i> , 2001
Streptomycin resistance gene	<i>ant (3'')</i>	CAGCGCAATGACATTCTTGC GTCGGCAGCGACATCCTTCG	294	van Overbeek <i>et al.</i> , 2001
Tetracycline resistance gene	<i>tet(A)</i>	TTGGCATTCTGCATTCCTC GTATAGCTTGCCGGAAGTCCG	494	Call <i>et al.</i> , 2003
Tetracycline resistance gene	<i>tet(B)</i>	CAGTGCTGTTGTTCATTAA GCTTGAATACTGAGTGTA	571	Call <i>et al.</i> , 2003
Tetracycline resistance gene	<i>tet(M)</i>	ATTTCCGCAAAGTTCAGACG CCGTCATGCAATTTGTGTTTC	536	Call <i>et al.</i> , 2003
Beta lactamase gene	<i>bla_{TEM}</i>	AAAGATGCTGAAGATCA TTTGGTATGGCTTCATTC	425	Henriques <i>et al.</i> , 2006
Beta lactamase gene	<i>bla_{SHV}</i>	GCGAAAAGCCAGCTGTCGGGC GATTGGCGGCGCTGTTATCGC	538	Henriques <i>et al.</i> , 2006
DNA gyrase	<i>gyrA</i>	GTGTGCTTTATGCCATGAG GGTTTCCTTTCCAGGTC	287	Gorgani <i>et al.</i> , 2009
Topoisomerase IV	<i>parC</i>	CATCGTCTACGCCATGAG AGCAGCACCTCGGAATAG	267	Gorgani <i>et al.</i> , 2009


RESULTS AND DISCUSSION

Eighteen isolates were subjected to pulsed-field gel electrophoresis (PFGE) analysis with *PacI* restriction digestion. The recognition sequence of *PacI* restriction digestion was TTA_AT_AT_A. Twenty-five distinct band sizes were observed upon gel electrophoresis. The banding patterns were converted to binary data and this data can be interpreted by SPSS software to form a dendrogram (Fig. 1).

**Fig. 1:** Phylogenetic diversity of *Pseudomonas aeruginosa* identified by PFGE.

It was able to group the 18 isolates into 3 genotypes at 20% dissimilarity cutoff value. Genotype 1 was more prevalent

(77.7%) (Fig. 2). Genotype 2 and genotype 3 were found to contain 11.11% of the isolates.

**Fig. 2:** Prevalence of genotypes.

Virulence factors of *Pseudomonas* spp. tightly regulated by cell to cell signaling systems was reported by Van Delden and Iglewski (1998). Total eighteen isolates were studied for virulence and antibiotic resistance genes. Out of eighteen isolates, 13 isolates had the L lipoprotein (*oprL*) with 504 bp gene product. de Vos *et al.* (1999), Masuda *et al.* (1995) and Nikaido (1994) previously described that *P. aeruginosa* contained outer membrane protein L (*oprL*) that is responsible for inherent resistance to antibiotics and antiseptics. This *oprL* gene is used as a marker for

rapid identification of *P. aeruginosa* species. According to previous studies (Pitt, 1998; Engel, 2003) collagen, C1q and C3 of the complement pathway, serum protease inhibitors, fibrin, fibrinogen, laminin and elastin are the substrates of alkaline protease, *apr*. Twelve isolates were found to possess *apr* gene and produce 1017 bp gene product. Hence the prevalence was 55.56%. Genotypic distributions were similar in genotype 2 and 3 (Fig. 3). All the isolates present in genotype 2 and 3 harboured *oprL* and *apr* genes (100%). Gene distribution patterns were different in genotype 1 and 64.29% and 57.14% present in genotype 1 carried *oprL* and *apr* genes, respectively.




Fig. 3: Genotypic distribution of *oprL* and *apr* genes.

Sabharwal *et al.* (2014) identified that only *P. aeruginosa* contained exotoxin A (*toxA*) gene, whereas other species of this genus did not yield *toxA* gene. Out of the 18 isolates, 10 (55.56%) isolates had the exotoxin A genes (*toxA*) with an approximate length of 250 bp. Hamood (2004) reported that protein biosynthesis is inhibited by the action of exotoxin A (*toxA*). Nikbin *et al.* (2012) described that *toxA* gene was found in 90.7% *P. aeruginosa* isolated from burn, wound and pulmonary tract infections sample. According to Riese *et al.* (2002) and Anthonv *et al.* (2007), type-III secretion system directly secrete exoenzyme S (*exoS*) into the cytosol of human epithelial cell and other studies (Olson *et al.*, 1999; Yahr *et al.*, 1996) found that this inactivated cellular function, inhibited DNA synthesis and microvillus effacement. Nine isolates were found to possess exoenzyme S (*exoS*) and gave 504 bp gene product. So, the percentage of prevalence was 50. Recently, Thamir and Jubori (2014) described that *exoS* gene was present in higher number in samples collected from cystic fibrosis patients, wound, urine and blood than from sputum and bronchial washer. The 283 bp gene product of *lasB* gene was found in nine isolates. Hence the prevalence was 50%. Sabharwal *et al.* (2014) reported that elastin, collagen, fibronectin and laminin are substrates of T2SS secreted proteolytic enzyme, *lasB* gene. Elastase, *lasB* gene showed elastolytic activity on human lung tissue and was reported by Lomholt *et al.* (2001). Phospholipase C (*plcH*) hydrolyzing phospholipid was reported by Sabharwal *et al.* (2014). The *plcH* gene produces 307 bp gene product and 13 isolates (72.22%) were found to express *plcH* genes. Proinflammatory activities and pulmonary inflammation caused by phospholipase C (*plcH*) was reported by Wieland *et al.* (2002). Terada *et al.* (1999) examined that oxidative burst of

neutrophils is also inhibited by phospholipase C (*plcH*). Genotypic distribution of exotoxin A (*toxA*), exoenzyme S (*exoS*), elastase (*lasB*) and phospholipase C (*plcH*) gene was similar in genotype 2 and 3 (Fig. 4). All the isolates present in genotype 2 and 3 harboured these four genes (100%). Low prevalence of *exoS* and *lasB* gene were encountered in genotype 1 (35.71%) while 42.86% and 64.29% isolates present in genotype 1 contained *toxA* and *plcH* genes, respectively.




Fig. 4: Genotypic distribution of *toxA*, *exoS*, *lasB* and *plcH* genes.

Isolates were also screened for rhamnolipid AB (*rhlAB*), alginate (*algD*) and putative neuraminidase (*nan2*). Isolates those harboured *plcH* genes were also found to be positive for rhamnolipid AB (*rhlAB*) gene. The *rhlAB* gene produces 151 bp gene product. Van and Iglewski (1998) reported that phospholipids of lung surfactant are solubilized by rhamnolipid and this solubilized phospholipid is more easily cleaved by phospholipid C (*plcH*). Thirteen isolates were found to possess alginate (*algD*) genes and produced 1311 bp gene product. Hence the prevalence was 72.22%. Govan and Deretic (1996) described that chronic pulmonary inflammation is caused by alginate (*algD*) gene. It also helps to escape host immune surveillance and provide protection from antibiotics. Putative neuraminidase (*nan2*) was found in 72.22% of the isolates with 1161 bp gene product. Daniel *et al.* (2007) reported that spreading of *P. aeruginosa* within the host cells is mediated by neuraminidase gene. Neuraminidase also required for implantation of the bacterium was described by Cacalano *et al.* (1992) and Davies *et al.* (1999). Genotypic distribution of *rhlAB*, *algD* and *nan2* gene was similar in all genotypes (Fig. 5). All the isolates present in genotype 2 and 3 carried these three genes (100%) while 64.29% isolates present in genotype 1 expressed all these three genes.




Fig. 5: Genotypic distribution of *rhlAB*, *algD* and *nan2* genes.

Antibiotic resistance is now a global concern. Isolates were tested for the streptomycin resistance genes. The *aph(6)-Id* gene produces 560 bp gene product and was present in *Pseudomonas aeruginosa* PA7. *P. aeruginosa* PA7 isolate was also found to express 515 bp gene product for *aph(3'')* gene. Only *P. aeruginosa* NCGM2.S1 isolate had the *ant(3'')* gene with 294 bp gene product. So, isolate *P. aeruginosa* PA7 harboured both *aph(3'')* and *aph(6)-Id* genes. Adesoji *et al.* (2015) also reported about a *Pseudomonas* bacterium that carried more than one streptomycin resistance genes. These isolates had the aminoglycoside modifying enzyme. Llano-Sotelo *et al.* (2002) reported that antibiotic molecule is modified by AMEs enzyme that linked antibiotic molecule with phosphate, adenylyl or acetyl radical. Thus, modified antibiotics could not bind with its target. Aminoglycoside modifying enzyme (AME) genes which includes *aac(6')-I* and *ant(2'')-I*, were found in 50 and 45% of *Pseudomonas* isolates, respectively as reported by Odumosu *et al.* (2003). Seveno *et al.* (2002) examined that streptomycin resistance is high in clinical and agricultural habitats. Genotype 2 and 3 carried no streptomycin resistance gene (Fig. 6). Gene distribution pattern was similar in genotype 1 and 14% isolates present in genotype 1 harboured these three genes.




Fig. 6: Genotypic distribution of streptomycin resistance genes.

Sulfonamide resistance gene, *sul1* was present in 2 isolates (11.11%) (*P. aeruginosa* NCGM2.S1, *P. aeruginosa* PA7) with an amplicon of 433 bp. No isolate harboured the *sul2* and *sul3* gene. Adesoji *et al.* (2015) also found sulfonamide resistance gene *sul1* (31.8%) and no *sul3* genes. But their study found *sul2* gene (27.3%). Only *P. aeruginosa* NCGM2.S1 had the *bla_{TEM}* gene with 425 bp gene product. The *bla_{SHV}* gene was not present in any one of the isolates. Adesoji *et al.* (2015) found that among the beta lactamase gene, *bla_{TEM}* gene was more prevalent (40.9%) than *bla_{SHV}* (27.3%). Bradford (2001) reported that enterobacteriaceae mainly harboured the enzyme, *bla_{TEM}* and *bla_{SHV}*. However, *Pseudomonas* harboured the *bla_{TEM}* and *bla_{SHV}* gene possibly due to the overuse of beta lactam antibiotics. Adesoji *et al.* (2015) examined that tetracycline resistance of *tet(A)*, *tet(B)*, and *tet(E)* gene is acquired by efflux pump system and for *tet(O)* and *tet(M)* gene, resistance mechanism is developed by ribosomal protection. No isolate was found that contained tetracycline resistance *tet(A)*, *tet(B)* or *tet(M)* gene. Zhang *et al.* (2009) stated that various

environmental genera carried the broad host range tetracycline resistance gene *tet(A)*. Shababi *et al.* (2011) studies found that the prevalence of *tet(B)* gene was higher than *tet(A)* gene of *P. aeruginosa* samples isolated from municipal sewage. Genotype 2 and 3 contained no sulfonamide, *sul1* or beta lactamase *bla_{TEM}* resistance genes (Fig. 7). The *sul1* and *bla_{TEM}* genes were present in 14.29% and 7.14% isolates in genotype 1.




Fig. 7: Genotypic distribution of *sul1* and *bla_{TEM}* genes.

Fazeli and Momtaz (2014) demonstrated that multiplex PCR assays were used to detect fluoroquinolone resistance-determining region of the *gyrA* and *parC* gene. Fourteen isolates were found to express *gyrA* genes with an approximate length of 287 bp. So, the percentage of prevalence was 77.78. Strateva and Yordanov (2009) described that *gyrA* gene is modified within the enzyme's active site, quinolone-resistant-determinative region by a point mutation and changed the amino acid sequence of A and B subunits. This alteration created low affinity quinolone molecules. PCR amplification of *parC* gene produces 267 bp gene product. Thirteen isolates (72.22%) had the *parC* genes. All the isolates present in genotype 2 and 3 carried *gyrA* and *parC* genes (100%) (Fig. 8). Genotype 1 also harboured *gyrA* and *parC* genes and 71.43% and 64.3% isolates present in genotype 1 expressed *gyrA* and *parC* genes, respectively.




Fig. 8: Genotypic distribution of *gyrA* and *parC* genes.

Class 1 integrase, *int1* was found in only isolate *Pseudomonas aeruginosa* NCGM2.S1. No isolate was found to harbour class 2 integrase, *int2*. Mazel (2006), Rowe-Magnus and Mazek (2002) studied class 1 integrase and described that class 1 integrase facilitate the ability to shuttle antibiotic resistance genes

between different bacterial species. Isolates *P. aeruginosa* NCGM2.S1 contained class 1 integron gene and is considered as a multidrug resistant bacterium. Variable region of class 1 integron was found in one isolate (*P. aeruginosa* NCGM2.S1). Adesoji *et al.* (2015) concluded that the variable region of class 1 integrase helps to insert antibiotic resistant cassette in the integrase sequence. Class 1 integrase and variable region of class 1 integron genes were absent in genotype 2 and 3 (Fig. 9). Genotype 1 harboured similar number of class 1 integrase and variable region of class 1 integron gene (7.14%).




Fig. 9: Genotypic distribution of class 1 integrase and variable region of class 1 integron.

CONCLUSION

Identification of L lipoprotein, *oprL* precisely and rapidly identify *P. aeruginosa* species. Gene distribution pattern of virulence and antibiotic resistance genes within genotypes were almost similar. Different virulent genes are identified that may contribute to virulence and pathogenicity of the infections. The data has provided epidemiological information to study the characteristics of the *P. aeruginosa* and also the virulence factors associated with infections. *Pseudomonas* harbouring class 1 integron spread the antibiotic resistance gene in the environment which is now a global concern. This multidrug resistant *Pseudomonas* may contribute to many emergence and re-emergence infectious diseases. Finally clinical studies are needed to control multidrug-resistant *Pseudomonas* and maximize the clinical outcomes in the treatment of infectious diseases.

Financial support and sponsorship: Nil.

Conflict of Interests: There are no conflicts of interest.

REFERENCES

Adesoji AT, Ogunjobi AA, Olatoye IO. Molecular characterization of selected multidrug resistant *Pseudomonas* from water distribution systems in southwestern Nigeria. *Ann. Clin Microbiol Antimicrob*, 2015; 14(1):39.

Anthony WM, Qing D, Michael SP, Bassam TW, Joseph TB. *Pseudomonas aeruginosa* *exoS* ADP-ribosyltransferase inhibits ERM phosphorylation. *Cellular Microbiol*, 2007; 9(1):97-105.

Bikandi J, San Millán R, Rementería A, Garaizar J. *In silico* analysis of complete bacterial genomes: PCR, AFLP-PCR and endonuclease restriction. *Bioinformatics*, 2004; 20(5):798-799.

Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis*, 2006; 43:49-56.

Bradbury RS, Roddam LF, Merritt A, Reid DW, and Champion AC. Virulence gene distribution in clinical, nosocomial and environmental isolates of *Pseudomonas aeruginosa*. *J Med Microbiol*, 2010; 59(8):881-890.

Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*, 2001; 14:933-51.

Cacalano G, Kays M, Saiman L, Prince A. Production of the *Pseudomonas aeruginosa* neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression. *J Clin Invest*, 1992; 89:1866-1874.

Call DR, Brockman FJ, Chandler DP. Detecting and genotyping *Escherichiacoli* O157:H7 using multiplexed PCR and nucleic acid microarrays. *Int J Food Microbiol*, 2003; 67:71-80.

Chen J, Su Z, Liu Y, Wang S, Dai X, Li Y, Peng S, Shao Q, Zhang H, Wen P, Yu J, Huang X, Xu H. Identification and characterization of class 1 integrons among *Pseudomonas aeruginosa* isolates from patients in Zhenjiang, China. *Int J Infect Dis*, 2009; 13:717-21.

Daniel GL, Jonathan MU, Gang W, Nicole TL, Rhonda LF, Sachiko M, Lenard TD, Jianxin H, Maude S, Eric D, Lisa F, Li L, George G, Kate M, Raju K, Laurence GR, Frederick MA. Genomic analysis reveals that *Pseudomonas aeruginosa* virulence is combinatorial. *Genome Biol*, 2007; 7:R90

Davies J, Dewar A, Bush A, Pitt T, Gruenert D, Geddes DM, Alton EW. Reduction in the adherence of *Pseudomonas aeruginosa* to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition. *Eur Respir J*, 1999; 13:565-570.

de Vos D, Lim A, Pirnay JP, Struelens M, Vandenveld C, Duinslaeger L, Vanderkelen A, Cornelis P. Direct detection and identification of *Pseudomonas aeruginosa* in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane genes, *oprI* and *oprL*. *J Clin Microbiol*, 1997; 35:1295-1299.

Engel JN. 2003. Molecular pathogenesis of acute *Pseudomonas aeruginosa* infections. In *Severe Infections Caused by Pseudomonas aeruginosa*, 201-229. Edited by A. R. Hauser & J. Rello. Dordrecht: Kluwer Academic Publishers.

Fazeli N, Momtaz H. Virulence gene profiles of multidrug-resistant *Pseudomonas aeruginosa* isolated from Iranian hospital infections. *Iran Red Crescent Med J*, 2014; 16(10):e15722.

Fegan M, Francis P, Hayward AC, Davis GH, Furest JA. Phenotypic conversion of *Pseudomonas aeruginosa* in cystic fibrosis. *J Clin Microbiol*, 1990; 28:1143-1146.

Gorgani N, Ahlbrand S, Patterson A, Pourmand N. Detection of point mutations associated with antibiotic resistance in *Pseudomonas aeruginosa*. *Int J Antimicrob Agents*, 2009; 34(5):414-8.

Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Microbiol Rev*, 1996; 60:539-574.

Hall RM, Collis CM. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. *Mol Microbiol*, 1995; 15:593-600.

Hamood AN, Colmer-Hamood JA, Carty NL. 2004. Regulation of *Pseudomonas aeruginosa* exotoxin A synthesis. In *Pseudomonas: Virulence and gene regulation*. Academic/plenum publishers, New York 389-423.

Henriques IS, Fonseca F, Alves A, Saavedra MJ, Correia A. Occurrence and diversity of integrons and β -lactamase genes among ampicillin-resistant isolates from estuarine waters. *Res Microbiol*, 2006; 157:938-47.

Houang AT, Chu YW, Lo WS, Chu KY, Cheng AF. Epidemiology of rifampin ADP ribosyltransferase (*arr-2*) and metallo- β -lactamase (*blaIMP-4*) gene cassettes in class 1 integrons in *Acinetobacter*

strains isolated from blood cultures in 1997 to 2000. *Antimicrob Agents Chemother*, 2003; 47:1382–90.

Khattab MA, Nour MS, El Sheshtawy NM. Genetic identification of *Pseudomonas aeruginosa* virulence genes among different isolates. *J Microb Biochem Technol*, 2015; 7:274-277.

Strateva, T, Yordanov D. *Pseudomonas aeruginosa*—a phenomenon of bacterial resistance. *J Med Microbiol*, 2009; 58(9):1133-1148.

Llano-Sotelo B, Azucena EF, Kotra LP, Mobashery S, and Chow CS. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. *Chem Biol*, 2002; 9:455–463.

Lomholt JA, Poulsen K, Kilian M. Epidemic population structure of *Pseudomonas aeruginosa*: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. *Infect Immun*, 2001; 69(10):6284–95

Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*, 1995; 39:645–649.

Mazel D. Integrons: agents of bacterial evolution. *Nat Rev Microbiol*, 2006; 4:608–20.

Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. *Science*. 1994; 264:382–388.

Nikbin VS, Aslani MM, Sharafi Z, Hashemipour M, Shahcheraghi F, Ebrahimipour GH. Molecular identification and detection of virulence genes among *Pseudomonas aeruginosa* isolated from different infectious origins. *Iran J Microbiol*, 2012; 4:118–23

Odumosu BT, Adeniyi BA, Chandra R. Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant *Pseudomonas aeruginosa* from Southwest Nigeria. *Ann Clin Microbiol Antimicrob*, 2013; 12:29–35.

Olson JC, Fraylick JE, McGuffie EM, Dolan KM, Yahr TL, Frank DW, Vincent TS. Interruption of multiple cellular processes in HT-29 epithelial cells by *Pseudomonas aeruginosa* exoenzyme S. *Infect Immun*, 1999; 67(6):2847–54.

Pitt TL, *Pseudomonas*, *Burkholderia*, and related genera. In: Balows A, Duerden BI, eds. *Topley and Wilson's Microbiology and Microbial Infections*, 1998; 2:1109-1138.

Pollack M. Principles and practice of infectious diseases, eds. In: Mandell, G. L., Bennet, J. E. and Dolin, R. (Churchill Livingstone, Philadelphia), 2000; 2:2310-2335.

Riese MJ, Goehring UM, Ehrmantraut ME, Moss J, Barbieri JT, Aktories K, Schmidt G. Auto-ADP-ribosylation of *Pseudomonas aeruginosa*. *ExoS J Biol Chem*, 2010; 277(14):12082-12088.

Roe MT, Vega E, Pillai SD. Antimicrobial resistance markers of Class 1 and Class 2 integron bearing *Escherichia coli* from irrigation water and sediments. *Emerg Infect Dis*, 2003; 9:822–6.

Rowe-Magnus DA, Mazel D. The role of integrons in antibiotic resistance gene capture. *Int J Med Microbiol*, 2002; 292:115–25.

Sabharwal N, Dhall S, Chhibber S, Harjai K. Molecular detection of virulence genes as markers in *Pseudomonas aeruginosa* isolated from urinary tract infections. *Int J Mol Epidemiol Genet*, 2014; 5(3):125.

San Millán RM, Martínez-Ballesteros I, Rementeria A, Garaizar J, Bikandi J. Online exercise for the design and simulation of PCR and PCR-RFLP experiments. *BMC Res Notes*, 2013; 6(1):513.

Seveno NA, Kallifidas D, Smalla K, van Elsas JD, Collard JM, Karagouni AD, Wellington EMH. Occurrence of reservoirs of antibiotic resistance genes in the environment. *Rev Med Microbiol*, 2002; 13:15–27

Shehabi AA, Haider AA, Fayyad MK. Frequency of antimicrobial resistance markers among *Pseudomonas aeruginosa* and *Escherichia coli* isolates from municipal sewage effluent water and patients in Jordan. *Int Arabic J Antimicrob Agents*, 2011; 1:1–5.

Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature*, 2000; 406:959–964.

Strateva Tanya, Daniel Yordanov. *Pseudomonas aeruginosa*—a phenomenon of bacterial resistance. *J Med Microbiol*, 2009; 58(9):1133-1148.

Terada LS, Johansen KA, Nowbar S, Vasil AI, Vasil ML. *Pseudomonas aeruginosa* hemolytic phospholipase C suppresses neutrophil respiratory burst activity. *Infect Immun*, 1999; 67(5):2371–6.

Thamir E, Al-Jubori, SS. Genetic detection of some virulence genes in *Pseudomonas aeruginosa* isolated from cystic fibrosis and non-cystic fibrosis patients in Iraq. *J Genet Environ Resour Conserv*, 2014; 2(3):380-387.

Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. *Am J Infect Control*, 2004; 32:177–183.

Van Delden C, Iglewski BH. Cell-to-cell signaling and *Pseudomonas aeruginosa* infection. *Emerg Infect Dis*, 1998; 4:551-560

van Overbeek LSV, Wellington EMH, Egan S, Smalla K, Heuer H, Collard JM, Guillaume G, Karagouni AD, Nikolakopoulou TL, Elsas JDVE. Prevalence of streptomycin-resistance genes in bacterial populations in European habitats. *FEMS Microbiol Ecol*, 2001; 42:277–88.

Vinue L, Saenz Y, Rojo-Bezares B, Olarte I, Undabeitia E, Somalo S, Zarazaga M, Torres C. Genetic environment of *sul* genes and characterisation of integrons in *Escherichia coli* isolates of blood origin in a Spanish hospital. *Int J Antimicrob Agents*, 2010; 35:492–6.

White PA, Mciver CJ, Rawlinson WD. Integrons and gene cassettes in the Enterobacteriaceae. *Antimicrob Agents Chemother*, 2001; 45:2658–61.

Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by *Pseudomonas aeruginosa* lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1. *Infect Immun*, 2002; 70(3):1352–8.

Yah SC, Eghafona NO, Enabulele IO. Prevalence of plasmids mediated *Pseudomonas aeruginosa* resistant genes from burn wound patients at the university of Benin teaching hospital Benin City. *Nigeria J Biomed Sci*, 2006; 5:61-8

Yahr TL, Goranson J, Frank DW. Exoenzyme S of *Pseudomonas aeruginosa* is secreted by a type III pathway. *Mol Microbiol*, 1996; 22(5):991–1003.

Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of *Pseudomonas aeruginosa* infections in a university hospital, Malatya, Turkey. *Am J Infect Control*, 2006; 34:188–192.

Zhang XX, Zhang T, Fang HHP. Antibiotic resistance genes in water environment. *Appl Microbiol Biotechnol*, 2009; 82:397–414.

How to cite this article:

Nahar N, Asad S, Ahmed T, Setu NI, Kayser MS, Islam MS, Islam MK, Rahman MM, Al Aman DAA, Rashid RB. *In silico* assessment of the genotypic distribution of virulence and antibiotic resistance genes in *Pseudomonas aeruginosa*. *J App Pharm Sci*, 2017; 7 (07): 055-061.